Nidda Investment Group Takes Full Ownership Of Stada Through Settlements With Shareholders
Executive Summary
Nidda Healthcare, investment vehicle controlled by Bain Capital and Cinven, secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of 10 euro cents per outstanding share for the remaining shareholders.
You may also be interested in...
OTC Innovation In An Age Of Pandemics – Q&A With Stada’s New R&D Head Stephen Makin
COVID-19 has shifted consumer health behaviour towards prevention and general wellbeing. However, finding out what consumers actually want and need is still the essence of good OTC innovation, according to Stada Arzneimittel's new vice president of consumer healthcare product development Steve Makin.
Blackstone Emerges As Likely Buyer For Takeda's OTC Business At Price Close To $3Bn
Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.
Nidda Sets Price For Stada Squeeze-Out
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.